BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Afferent Pharmaceuticals 

29 Newbury Street
Suite 301
Boston  Massachusetts  02116  U.S.A.
Phone: 617-859-3099 Fax: 617-859-2891


SEARCH JOBS




Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Afferent Pharmaceuticals Announces The Election Of Dr. Peter Hirth To The Company’s Board Of Directors 12/3/2014 8:45:11 AM
Afferent Pharmaceuticals Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency By 75% in Chronic Cough Is Published In The Lancet 11/25/2014 6:37:44 AM
Afferent Pharmaceuticals Names Kathleen Sereda Glaub As Chief Executive Officer 9/10/2014 6:27:42 AM
Afferent Pharmaceuticals Names Michael M. Kitt, M.D., as Chief Medical Officer 11/6/2013 9:15:37 AM
Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 9/9/2013 9:44:08 AM
Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain 9/1/2010 8:42:05 AM
Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes 8/25/2010 10:12:23 AM
Roche (RHHBY) (JOBS) Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing 12/16/2009 6:31:41 AM